However, in light of previous reports revealing a physical interaction of EZH2 and the p53 antagonist MDM2 [75] and recent findings suggesting EZH2 as a specific and important inducer of the translation of the p53 mutant protein in prostate cancer [76], non-canonical EZH2 functions might additionally contribute to the increased protein turnover of p53wt in EZH2-proficient PDAC. Here, TP53 is linked to prostate carcinoma.